Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 240-540-6 | CAS number: 16485-10-2
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Link to relevant study record(s)
Description of key information
DL- Panthenol is expected to be systemically absorbed after oral and dermal exposure. Based on its physical chemical properties, the substance is not expected to diffuse into intracellular compartments. Moreover distribution through extracellular body fluids is likely. It is expected, that DL- Panthenol undergoes a first- pass effect in the liver after oral application. Metabolism will most likely include phase I enzymes and will result in the quick formation of Pantothenic acid. Excretion of the breakdown products will most likely occur via the urine. No bioaccumulation is expected.
Key value for chemical safety assessment
- Bioaccumulation potential:
- no bioaccumulation potential
Additional information
Absorption:
With a molecular weight of 205.25 g/mol, a logKow value of -1.02 and a water solubility of 562.3 g/L DL‑ Panthenol is likely to be absorbed in the GI tract. Due to the high water solubility the substance may not diffuse across plasma membranes. More likely gastro-intestinal absorption of DL- Panthenol is triggered by passage through aqueous pores or carriage with the bulk passage of water which is favoured for small (molecular weight around 200 g/mol), water soluble substances. Since there is an active transport mechanism for Pantothenic acid, active transport may also be likely for DL- Panthenol. It remains unclear if the active transport is enantiomer- specific as only the D- form of Pantothenic acid is transported. Nevertheless, extensive gastrointestinal absorption is expected for DL‑ Panthenol based on physical chemical properties.
Based on the low vapour pressure of 0.0036 Pa DL‑ Panthenol does not vaporise in a sufficient manner to become available for inhalation exposure. Exposure to aerosols may occur. However, due to the high water solubility the substance is likely to solve in the mucus lining of the respiratory tract but subsequent systemic absorption is not likely.
The substance characteristics and physical-chemical properties indicate that dermal absorption is likely. The physical state favours quick dermal absorption with liquids taken up more readily than dry particulates. Data available for D- Panthenol show that dermal absorption occurred following topical administration to rats, which was proven by the higher urinary excretion of Pantothenic acid, the oxidation product of D- Panthenol, in comparison to controls (Erlemann et al, 1962).In vitro dermal penetration studies with D- Panthenol using rat and pig skin also showed that dermal penetration occurred (unpublished DSM Nutritional Products Reports, Klecak, 1985). In conclusion, the available data suggest that DL- Panthenol will be systemically absorbed after skin exposure.
Distribution:
Following oral and dermal absorption DL- Panthenol is likely to systemically distribute through extracellular compartments. Data obtained from oral subchronic repeated dose toxicity testing give not rise to any target organ specificity. As D- Panthenol was shown to be rapidly metabolised to Pantothenic acid it may be concluded that DL- Panthenol undergoes a first pass effect in liver after oral application, indicating that distribution of the parent compound is limited through oral routes. Furthermore, oral absorption may be limited by microbiological degradation in the intestine. However, systemic distribution following dermal exposure is expected for DL- Panthenol, based on the toxicokinetic behaviour of the pure D‑ enantiomer of Panthenol (Erlemann et al, 1962). The low half life, based on the presumed rapid metabolic degradation and subsequent quick urinary excretion, indicate a low potential for bioaccumulation. In addition, the low logKow of -1.02 also indicates a very low bioaccumulation potential.
Metabolism:
Based on the chemical structure, the substance may be metabolised by phase I and II enzymes, mainly in the liver. Initial alcohol oxidation by cytochrome P450 monooxygenases (CYP) or alcohol and aldehyde dehydrogenases (ADH/ AlDH) will result in the generation of Pantothenic acid (vitamin B5). Results obtained from D- Panthenol indicate quick oxidation to Pantothenic acid and it is expected that DL- Panthenol is metabolised through the same enzymatic pathways. Further, a hydrolysis of the amide- bond is proposed resulting in 2,4‑ Dihydroxy-3,3-dimethyl-butyric acid and 3- Hydroxypropylamine. The parent compound as well as Pantothenic acid and the hydrolysis products may be readily conjugated by phase II metabolising enzymes like Glucuronosyltransferases and Sulfotransferases. No conversion into a toxic metabolite is expected as indicated by in vitro genetic toxicity tests performed with DL‑ Panthenol and DL- Ethyl Panthenol.
Excretion
Data obtained from testing with D- Panthenol in rats indicate, that topical administered substance is quickly metabolised to Pantothenic acid, which is rapidly excreted via the urine. Similar is expected for DL- Panthenol, as metabolism of the parent compound will result into Pantothenic acid as well, triggered by the same enzymatic pathways. If administered orally, excretion may also occur via faeces as metabolic degradation via the intestinal microflora is expected.
In conclusion, DL- Panthenol is expected to be systemically absorbed after oral and dermal exposure. Based on its physical chemical properties, the substance is not expected to diffuse into intracellular compartments. Moreover distribution through extracellular body fluids is likely. It is expected, that DL- Panthenol undergoes a first- pass effect in the liver after oral application. Metabolism will most likely include phase I enzymes and will result in the quick formation of Pantothenic acid. Excretion of the breakdown products will most likely occur via the urine. No bioaccumulation is expected.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.